Polyrizon Ltd. (NASDAQ:POLY), a biopharmaceutical company, announced today the appointment of Liron Carmel to its Board of Directors, effective immediately. Mr. Carmel, who brings a wealth of experience from various industries, has rejoined the board after a previous tenure.
The company disclosed in a filing with the Securities and Exchange Commission that the appointment was approved by its Board of Directors on Monday. Mr. Carmel is currently the CEO of Xylo Technologies Ltd. (NASDAQ:XYLO), a company with a market capitalization of $3.46 million and annual revenue of $57.6 million. According to InvestingPro analysis, Xylo is currently trading below its Fair Value, with analysts setting a unanimous target price of $12 per share. Mr. Carmel has a diverse background that spans biopharma, technology, and financial services.
His previous roles include serving as CEO and director of CannaPowder (PINK:CAPD), a bio-pharma company in the cannabinoid field, and as a director for Chiron Refineries Ltd. (TASE:CHR) and Gix (TASE:GIX), both Israeli public companies. Mr. Carmel also has experience in municipal development and investment management, highlighting his broad expertise in business and strategy. InvestingPro subscribers have access to 8 additional key insights about Xylo Technologies, including detailed financial health metrics and growth indicators.
Polyrizon's addition of Mr. Carmel to the board is part of the company's ongoing efforts to strengthen its leadership as it advances in the pharmaceutical preparations industry. The company, headquartered in Raanana, Israel, operates under the organization name 03 Life Sciences and is incorporated in L3.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.